Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Med Klin Intensivmed Notfmed ; 116(2): 121-128, 2021 Mar.
Article in German | MEDLINE | ID: mdl-33564900

ABSTRACT

BACKGROUND: CAR­T cell therapy has been implemented as clinical routine treatment option during the last decade. Despite beneficial outcomes in many patients severe side effects and toxicities are seen regularly that can compromise the treatment success. METHODS: Literature review: CAR T­cell therapy, toxicities and their management RESULTS: The cytokine release syndrome (CRS) and the immune effector cell-associated neurotoxicity syndrome (ICANS) are seen regularly after CAR T­cell treatment. CRS symptoms can range from mild flu-like symptoms to severe organ dysfunction requiring vasopressor therapy, mechanical ventilation and other intensive care support. ICANS symptoms usually develop later and can range from disorientation and aphasia to potentially life-threatening brain edema. IL­6 is a key factor in the pathophysiology of CRS. The pathophysiology of ICANS is not fully understood. The ASTCT consensus grading is recommended to stratify patients for different management options. An interdisciplinary team including hematologist, intensivist, neurologists and other specialties is needed to optimize the treatment. DISCUSSION: Severe and potentially life-threatening toxicities occur regularly after CAR T­cell therapy. Treatment strategies for CRS and ICANS still need to be evaluated prospectively. Due to the increasing number of patients treated with CAR T­cells the number of patients requiring temporary intensive care management due to CRS and ICANS is expected to increase during the next years.


Subject(s)
Critical Illness , Immunotherapy, Adoptive , Critical Care , Critical Illness/therapy , Cytokine Release Syndrome , Humans , T-Lymphocytes
2.
J Infect Chemother ; 25(4): 298-301, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30482700

ABSTRACT

Raoultella planticola is a gram-negative, encapsulated, aerobic bacterium within the Enterobacteriaceae family. It has been primarily described as pathogen in cases with pneumonia and gastrointestinal infections. Here we describe a case of severe pelvic cellulitis in a patient with neutropenia following induction therapy for myeloid sarcoma. The patient experienced a septic shock and was treated successfully with antibiotic therapy. A literature review is provided to put this case in context with previous reports on R. planticola. This report highlights that awareness for uncommon pathogens is crucial in the clinical management of infections in neutropenic patients.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cellulitis/microbiology , Chemotherapy-Induced Febrile Neutropenia/complications , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae/isolation & purification , Adult , Cellulitis/complications , Cellulitis/diagnosis , Cellulitis/drug therapy , Chemotherapy-Induced Febrile Neutropenia/diagnosis , Chemotherapy-Induced Febrile Neutropenia/etiology , Enterobacteriaceae Infections/complications , Enterobacteriaceae Infections/diagnosis , Enterobacteriaceae Infections/drug therapy , Humans , Magnetic Resonance Imaging , Male , Pelvis/diagnostic imaging , Sarcoma, Myeloid/drug therapy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...